; sense of Congress (a) Findings Congress finds the following: (1) The Government of the People’s Republic of China (PRC) seeks to dominate biotechnology as an industry of the future. (2) In recent years, the PRC has pursued a strategy known as military-civil fusion that merges public and private industries to enable the military modernization of the People’s Liberation Army (PLA). (3) In the PRC’s 14th Five-Year Plan, the PRC emphasized the use of artificial intelligence for biological discovery and called to accelerate the development of biotechnology. (4) PRC biotechnology companies have repeatedly collaborated with PLA entities, including Third Military Medical University and the PLA’s Key Laboratory of High-Altitude Medicine. (5) PRC law requires companies that are controlled by a PRC entity, like BGI, to comply with PRC national security laws, which provide the Chinese Communist Party (CCP) with the power to compel Chinese companies to turn over their data. (6) Pursuant to the PRC’s laws, the PRC can require a company headquartered in the PRC to surrender all its data to the Government of the PRC, making it an espionage tool of the CCP. (7) The National Intelligence Law, passed in China in 2017, states that any organization must assist or cooperate with CCP intelligence work. (8) China’s 2014 counter-espionage law also states that relevant organizations … may not refuse to collect evidence for an investigation. (9) The PRC’s Data Security Law of 2021 states that the Government has the power to access and control private data. (10) The PRC’s counter-espionage law grants PRC state security agencies nearly unfettered discretion, if acting under an effectively limitlessly capacious understanding of national security, to access data from companies. (11) The executive branch has determined that BGI, formerly known as Beijing Genomics Institute, is a national security threat. (12) In October 2022, the Department of Defense added BGI Genomics Co., LTD (BGI) to the Department of Defense’s list of PRC Military